prIME Masterclass in Neuroendocrine Tumors

prIME Masterclass in Neuroendocrine Tumors

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

Meeting Overview

Apply now to engage with experts in the field of neuroendocrine tumors (NETs) by joining this highly interactive 1.5-day live meeting. Our experts will provide a comprehensive update on the management of NETs, focusing on recent developments in imaging and therapeutic options by using the following strategies:

  • Didactic presentations
  • Interactive workshops
  • Case-based presentations and clinical management discussions
  • “Beat the Experts” NETs quiz
  • Q & A sessions

Date and Location

Friday and Saturday
16 – 17 November 2018

Room: Saal A+B
Steigenberger Hotel Berlin
Los-Angeles-Platz 1
Berlin, Germany

Travel Grant Information

To apply for a travel grant, click on the Apply Now button.



Friday & Saturday
16 – 17 November 2018



Berlin, Germany



Friday, 16 November—Day 1

10.30 Registration
12.00 Lunch
13.00 Welcome and introduction
Dermot O’Toole, MD, FRCPI, and Philippe Ruszniewski, MD

Session I: Biology, Pathology, and Prognosis
Moderators: Ulrich-Frank Pape, MD, and Philippe Ruszniewski, MD

13.15 Determining prognosis in NETs: Clinical, radiologic, and biologic markers—Are they really useful?
Ulrich-Frank Pape, MD
13.45 Update on cellular pathways in NET behavior
13.45 Somatostatin receptor pathways
Leo Hofland, PhD
14.10 Update on genomics in NETs
Bertram Wiedenmann, MD, PhD
14.30 Interactive clinician-focused pathology workshop & 2017 classification updates
Jean-Yves Scoazec, MD, PhD
15.15 Coffee break

Session II: Imaging and Surgery
Moderators: Massimo Falconi, MD, and Dermot O’Toole, MD, FRCPI

15.45 Imaging and image-guided therapy for gastroenteropancreactic (GEP) NETs
Maxime Ronot, MD, PhD
16.15 Surgical challenges in NET management
16.15 Pancreatic NETs
Massimo Falconi, MD
16.30 Intestinal NETs
Reza Kianmanesh, MD, PhD
16.45 Liver metastases
Sébastien Gaujoux, MD, PhD
17.00 Panel discussion and Q & A
17.15 Evening break
19.00 Reception
19.30 Dinner

Saturday, 17 November—Day 2

08.00 Breakfast

Session III: Therapy and Patient Care
Moderators: Marianne Pavel, MD, and Philippe Ruszniewski, MD

08.45 Keynote lecture—Systemic therapy for NETs: Current options and challenges
Marianne Pavel, MD
09.10 Q & A
09.20 Radiopharmaceuticals in NETs: Current and future state of therapy
Giovanni Paganelli, MD
09.50 Case-based presentations and clinical management discussions
09.50 Pancreatic NETs
Philippe Ruszniewski, MD
10.10 Intestinal NETs
Dermot O’Toole, MD, FRCPI
10.30 Pulmonary NETs
Jaume Capdevila, MD, PhD
10.50 Q & A
11.00 Coffee break

Session IV: Improving Patient Outcomes and Research Strategies
Moderators: John Ramage, MD, MB, BS, FRCP, and Dermot O’Toole, MD, FRCPI

11.30 Quality of life and the patient experience
John Ramage, MD, MB, BS, FRCP, and Catherine Bouvier
12.00 Keynote lecture—Clinical trials in NETs: How can we do better?
Jaume Capdevila, MD, PhD
12.25 Q & A
12.35 Lunch

Session V: Developing Specialist Expertise
Moderators: Jaume Capdevila, MD, PhD, and Philippe Ruszniewski, MD

13.35 “Beat the Experts” NETs quiz
Dermot O’Toole, MD, FRCPI, and Philippe Ruszniewski, MD
14.00 Where are we going with our understanding and treatment of NETs in 2019?
14.00 Basic science
Leo Hofland, PhD
14.15 Diagnosis and pathology
Jean-Yves Scoazec, MD, PhD
14.30 Treatment
Bertram Wiedenmann, MD, PhD
14.45 Q & A
14.55 prIME Points™ and closing remarks
Dermot O’Toole, MD, FRCPI, and Philippe Ruszniewski, MD
15.00 Afternoon tea break and adjourn


  • Dermot O’Toole, MD, FRCPISt Vincent’s University Hospital
    St James's Hospital
    Trinity College Dublin
    Dublin, Ireland
  • Philippe Ruszniewski, MDParis University
    Beaujon Hospital
    Clichy, France

  • Catherine BouvierNET Patient Foundation
    London, United Kingdom
  • Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Massimo Falconi, MDUniversity Vita-Salute San Raffaele
    IRCCS San Raffaele Hospital
    Milan, Italy
  • Sébastien Gaujoux, MD, PhDHospital Cochin, AP-HP
    Paris Descartes University
    Paris, France
  • Leo Hofland, PhDErasmus Medical Center
    Rotterdam, the Netherlands
  • Reza Kianmanesh, MD, PhDR. Debré University Hospital
    Reims, France
  • Giovanni Paganelli, MDIRST-IRCCS
    Meldola, Italy
  • Ulrich-Frank Pape, MDCharité University Hospital
    Berlin, Germany
  • Marianne Pavel, MDUniversity Hospital Erlangen
    Erlangen, Germany
  • John Ramage, MD, MB, BS, FRCPHampshire Hospitals NHS Trust
    Hampshire, United Kingdom
  • Maxime Ronot, MD, PhDBeaujon University Hospital
    Clichy, France
  • Jean-Yves Scoazec, MD, PhDGustave Roussy
    Villejuif, France
  • Bertram Wiedenmann, MD, PhDCharité University Hospital
    Charité Virchow Campus Clinic
    Berlin, Germany
Co-Chair Invitation

Co-Chair Invitation

Video Recap of <em>prIME Masterclass in NETs 2017</em>

Video Recap of prIME Masterclass in NETs 2017

This educational activity is designed for European medical oncologists, endocrinologists, gastroenterologists, nuclear medicine specialists, and other healthcare providers involved in the management of patients with NETs.

After successful completion of this educational activity, participants should be able to:

  • Describe the epidemiology, clinical characteristics, and natural history of NETs
  • Understand the cellular pathways of relevance in NETs and the role of molecular pathology in patient management
  • Select appropriate therapy from the increasing range of therapeutic options available for first and subsequent lines of treatment
  • Identify the potential for novel therapeutic strategies in the treatment of NETs

This educational activity is supported by Ipsen.

Continuing Education

prIME Masterclass in Neuroendocrine Tumors: A Multidisciplinary Interactive Workshop
held in Berlin, Germany on 16 – 17 November 2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Ärztekammer Berlin
prIME Oncology has received 10 CME-credits category A from the Ärztekammer Berlin for the German participants for “prIME Masterclass in Neuroendocrine Tumors: A Multidisciplinary Interactive Workshop” meeting (VNR 2761102018036000002).

Royal College of Physicians
prIME Masterclass in Neuroendocrine Tumors: A Multidisciplinary Interactive Workshop has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 8 category 1 (external) CPD credits.

Good CME Practice


This activity is provided by prIME Oncology.

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.